DCM
GBT

Dialectic Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Dialectic Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-51,000
Closed -$1.18M – 115
2016
Q3 		$1.18M Buy
51,000
+31,000
+155% +$591K 0.73% 40
2016
Q2 		$332K Buy
+20,000
New +$403K 0.11% 89

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dialectic Capital Management's GBT Position: Q4 2016 in Review

Dialectic Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2016, closing a stake of 51,000 shares — an estimated $1.18M sold.

Dialectic Capital Management first reported a position in GBT in Q2 2016 and held it in 2 quarters. The position peaked at $1.18M in Q3 2016. 96 funds tracked by Wall St. Rank hold GBT as of Q4 2016.

  • Dialectic Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Dialectic Capital Management sold 51,000 Global Blood Therapeutics, Inc. shares in Q4 2016, an estimated $1.18M.
  • Dialectic Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • Dialectic Capital Management's Global Blood Therapeutics, Inc. position peaked at $1.18M in Q3 2016.
  • 96 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2016.

Based on Dialectic Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.